Tocagen Inc. expanded its phase II/III clinical trial Toca 5, and is now enrolling patients in Canada. The trial first began enrolling patients in the U.S. in December 2015.
Researchers at Baylor College of Medicine, Texas Children’s Hospital, the University of Manitoba, and collaborating institutions revealed an unexpected way in which the protein OTX2 drives the progression of medulloblastoma—the most common aggressive childhood brain cancer.
